Details of the Drug

General Information of Drug (ID: DMWYEDX)

Drug Name

ON-01210.Na

Synonyms

Ex-RAD; Tyrosine kinase inhibitor (radiation protection), Onconova; ON-01210.Na (oral, radiation sickness); ON-01210.Na (oral, radiation sickness), Onconova; ON-01210.Na (sc, radiation sickness), Onconova Therapeutics

Indication

Disease Entry	ICD 11	Status	REF
Acute radiation syndrome	NF00	Phase 1	[1]
Radiation syndrome	NF00	Phase 1	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski):
0

Molecular Weight

358.8

Logarithm of the Partition Coefficient

Not Available

Rotatable Bond Count

5

Hydrogen Bond Donor Count

0

Hydrogen Bond Acceptor Count

4

Chemical Identifiers

Formula: C16H12ClNaO4S
IUPAC Name: sodium;4-[(E)-2-[(4-chlorophenyl)methylsulfonyl]ethenyl]benzoate
Canonical SMILES: C1=CC(=CC=C1CS(=O)(=O)/C=C/C2=CC=C(C=C2)C(=O)[O-])Cl.[Na+]
InChI: InChI=1S/C16H13ClO4S.Na/c17-15-7-3-13(4-8-15)11-22(20,21)10-9-12-1-5-14(6-2-12)16(18)19;/h1-10H,11H2,(H,18,19);/q;+1/p-1/b10-9+;
InChIKey: PRFBWBYKWZVQJF-RRABGKBLSA-M

Cross-matching ID

PubChem CID: 23668369
CAS Number: 922139-31-9
TTD ID: D02ESL

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
PI3K/AKT/mTOR pathway (PAm pathway)	TTGQUFK	NOUNIPROTAC	Inhibitor	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020974)
3	ON01210.Na (Ex-RAD ) mitigates radiation damage through activation of the AKT pathway. PLoS One. 2013;8(3):e58355.